ChemoID is a CLIA-certified and CAP-accredited drug response assay designed to help physicians’ select appropriate chemotherapy for an individual patient. ChemoID is a functional test that uses patient’s live tumor cells to indicate which chemotherapy agent (or combinations) will kill not only the bulk tumor cells, but also the CSCs that are known to cause cancer to recur.
Targeting of CSCs alongside the bulk of other cancer cells is a new paradigm in cancer treatment. This constitutes an important advantage of the ChemoID approach over other diagnostic methods in the market.
During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs. The drug response assay measures the effect of actual doses of standard-of-care chemotherapies on cancer stem cells. The ChemoID assay reports a prioritized list of effective and ineffective chemotherapies.
The ChemoID drug response assay is designed to target CSCs to mitigate relapse.
The ChemoID Drug Response Assay uses specimens obtained from a patient’s biopsy. The samples are shipped to our laboratory for stem cell enrichment and screening of FDA approved cytotoxic therapies. The results of the ChemoID assay are used to identify the most appropriate and effective drugs against cancer stem cells and the bulk of tumor cells for each patient.
ChemoID testing begins with a small tumor sample biopsy that is sent to our lab where the cancer cells are grown for testing. The process involves growing bulk tumor cells and enrichment of cancer stem cells from individual patient biopsies or recovered from fluid specimens. Those cells then are treated with various standard of care FDA approved chemotherapeutic agents selected by the patient’s oncologist to determine how many tumor-derived cells and CSCs are killed using each drug or combinations. A response curve is generated for each drug evaluated, and the data are presented graphically as the cytotoxic index for the oncologist.
ChemoID test results are reported to the oncologist in 14 days for surgical and fluid biopsy specimens and 20 days for core biopsies, to positively impact patient outcomes.
The market demand for a patient-centric approach to manage costs and enhance patient treatment outcomes in a timely and useful manner is precisely the evolution in Personalized Cancer Treatment that ChemoID is uniquely enabled to provide.
Entra in un mondo di opportunità su Hellspin dove ogni giro può trasformarsi in una vincita straordinaria.
